Treprostinil, sold under the brand names Remodulin for infusion, Orenitram for oral, and Tyvaso for inhalation among others, is a vasodilator that is used for the treatment of pulmonary arterial hypertension.

Treprostinil was approved for use in the United States in May 2002.

Treprostinil is indicated for the treatment of pulmonary arterial hypertension in people with NYHA Class II-IV symptoms to diminish symptoms associated with exercise.

Treprostinil inhalation solution and treprostinil inhalation powder are indicated for the treatment of people with pulmonary arterial hypertension (WHO Group 1) to improve exercise ability; and people with pulmonary hypertension associated with interstitial lung disease (WHO Group 3) to improve exercise ability.

In the European Union, treprostinil (Trepulmix) is indicated for the treatment of adults with WHO Functional Class III or IV and inoperable chronic thromboembolic pulmonary hypertension; or persistent or recurrent chronic thromboembolic pulmonary hypertension after surgical treatment to improve exercise capacity.

Common side effects depending on route of administration:

In 1976, the first paper on prostacyclin was published.

Treprostinil (Remodulin) was approved for medical use in the United States in May 2002, and again in July 2018.